Certara Sells Regulatory Writing Business to Veristat for Up to $135M
Certara announced that it has entered into a definitive agreement to sell its regulatory and medical writing business to Veristat for a consideration of up to $135M. The transaction is expected to close during the second quarter of 2026 subject to customary closing conditions. In 2025, the regulatory and medical writing business generated $50 million in revenue and $17 million in adjusted EBITDA, excluding unallocated overhead expense. The Regulatory and Medical Writing business includes approximately 220 employees. Certara plans to update its 2026 guidance to reflect the sale of the regulatory and medical writing business upon transaction close.
